However, the tool is composed of six different models depending on the type of treatment administered (anthracyclines, HER2 (human epidermal growth factor receptor 2) targeted therapies, vascular endothelial growth factor (VEGF) inhibitors, BCR-ABL (Breakpoint cluster region Abelson murine leukaemia viral oncogene homolog 1) inhibitors, multiple myeloma therapies, and RAF (rapidly accelerated fibrosarcoma) and MEK (mitogen activated protein kinase) inhibitors). This evidence concerns the gene ERBB2 and plasma cell myeloma.